Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.865
Abstract: Venglustat is a small‐molecule glucosylceramide synthase (GCS) inhibitor designed to reduce the production of glucosylceramide (GL‐1) and thus is expected to substantially reduce formation of glucosylceramide‐based glycosphingolipids. Because of its effect on glycosphingolipid formation, GCS… read more here.
Keywords: safety tolerability; safety; healthy volunteers; pharmacokinetics pharmacodynamics ... See more keywords
SAT-112 CLINICAL TRIAL OF VENGLUSTAT, A GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITOR, IS SUPPORTED BY PRECLINICAL AND PHASE 1 STUDY DATA
Sign Up to like & getrecommendations! Published in 2019 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2019.05.140
Abstract: results In three mouse models of PKD, treatment with a GCS inhibitor resulted in decreased kidney and plasma levels of glucosylceramide (GL-1) and reduced formation of kidney cysts compared with untreated controls. Analysis of kidney… read more here.
Keywords: gcs; venglustat; gcs inhibitor; kidney ... See more keywords